Active Ingredient(s):Dabrafenib Mesylate FDA Approved: * May 29, 2013 Pharm Company: *GLAXOSMITHKLINE Category:Cancer
Dabrafenib, sold under the brand name Tafinlar & Rafinlar ( both by Novartis) among others, is a medication for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF (V600)-mutated metastatic melanoma.[...
* May have multiple approval dates, manufacturers, or labelers.